10-Q: Immunome Reports Q2 2026 Results, Expenses Rise

Immunome, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing increased operating expenses and net losses, alongside progress in its oncology therapy pipeline.

Summary

• Immunome, Inc. reported its financial results for the second quarter of 2026, ending June 30, 2026.
• The company experienced a net loss of $73.1 million for the three months ended June 30, 2026, compared to a net loss of $43.4 million for the same period in 2025.
• Total operating expenses increased to $78.1 million from $50.5 million year-over-year.
• Research and development expenses rose to $59.9 million from $40.5 million, while general and administrative expenses increased to $18.3 million from $10.0 million.
• Cash and cash equivalents decreased significantly to $217.7 million as of June 30, 2026, from $653.5 million as of December 31, 2025.
• The company advanced its pipeline, with varegacestat's NDA accepted by the FDA with a target action date of April 28, 2027, and plans for an MAA submission in Europe by year-end 2026.
• Phase 1 trials for IM-1021, IM-1617, and IM-3050 are ongoing, with initial data for IM-1021 expected in 2026.
• The company expects its current cash, cash equivalents, and marketable securities to be sufficient for at least 12 months from the filing date.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant increases in operating expenses and continued net losses, despite progress in clinical trials.

Positives

• Varegacestat NDA accepted by FDA with a PDUFA target action date of April 28, 2027.
• Plans to submit an MAA for varegacestat with the EMA by the end of 2026.
• Phase 1 trial for IM-1617 dosed first participant in June 2026.
• Phase 1 trial for IM-3050 dosed first participant in July 2026.
• Positive topline results from the Phase 3 RINGSIDE trial for varegacestat were announced in December 2025.
• Objective response rate for varegacestat was 56% compared to 9% for placebo in the Phase 3 trial.
• Significant improvement in pain intensity scores observed with varegacestat in the Phase 3 trial.
• Increased interest income to $5.0 million for the quarter, driven by higher cash balances.

Negatives

• Net loss for the three months ended June 30, 2026, was $73.1 million, an increase from $43.4 million in the prior year period.
• Total operating expenses increased by $27.6 million to $78.1 million for the three months ended June 30, 2026.
• Research and development expenses increased by $19.4 million to $59.9 million for the three months ended June 30, 2026.
• General and administrative expenses increased by $8.2 million to $18.3 million for the three months ended June 30, 2026.
• Cash and cash equivalents decreased by $435.7 million to $217.7 million from December 31, 2025, to June 30, 2026.
• Net cash used in operating activities was $120.3 million for the six months ended June 30, 2026.
• The company has a history of losses and expects to continue incurring significant losses.
• The company has not generated any product revenue to date.

Risks

• The company has a history of losses and expects to continue incurring significant losses for the foreseeable future and may never achieve or maintain profitability.
• The company has a limited operating history, which may make it difficult to evaluate its drug development capabilities and predict its future performance.
• The company may be unable to advance any of its product candidates into and through clinical development, obtain regulatory approvals, and ultimately commercialize them, or it could experience significant delays in doing so.
• The market price of its common stock is expected to be volatile, and purchasers could incur substantial losses.
• The company may not be able to attract and retain qualified key management, technical personnel, and employees, which would impair its ability to implement its business plan.
• The company relies on third parties for manufacturing, supply, and testing, and any interruption or quality issue could impact its programs.
• The company's future capital requirements are substantial, and it may need to raise additional capital through equity offerings, which could dilute existing stockholders.
• The company is subject to stringent and evolving U.S. and foreign laws, regulations, and rules related to data privacy and security.

Future Outlook

The company expects its existing cash, cash equivalents, and marketable securities as of June 30, 2026, to be sufficient to fund its current and planned operating expenses and capital expenditures for at least 12 months from the filing date. However, it anticipates substantial increases in expenses to advance its pipeline and prepare for potential commercialization, indicating a need for additional capital beyond this period.

Management Comments

• Our goal is to establish a broad portfolio of differentiated clinical assets to improve the lives of cancer patients.
• We believe that combining novel targets with a broad toolbox of linkers and payloads supports our mission to design and develop a diverse pipeline of ADCs that address unmet medical need.
• We expect that our research and development expenses will increase substantially in connection with the continuation of our activities and new agreements.
• We anticipate that our general and administrative expenses will increase in the future to support increased and progressed research and development activities, activities to prepare for the potential commercialization of varegacestat, and increased activities and costs to operate as a public company.

Industry Context

StockSavvy.ai notes that Immunome's focus on targeted oncology therapies, particularly antibody-drug conjugates (ADCs), aligns with a major trend in the pharmaceutical industry. The significant investment in R&D and the progression of multiple clinical candidates reflect the high-risk, high-reward nature of biotechnology companies in this space. The company's challenges in managing expenses and achieving profitability are common among early-stage biotechs.

Comparison to Industry Standards

• Immunome's R&D spending as a percentage of total operating expenses is high, which is typical for biotechnology companies in the clinical development phase, aiming to bring novel therapies to market.
• The company's net loss and cash burn rate are consistent with industry peers that are heavily investing in pipeline development rather than revenue generation.
• The progression of varegacestat to an NDA submission and the ongoing Phase 1 trials for other candidates are milestones that align with industry benchmarks for advancing drug candidates.
• The company's reliance on equity financing to fund operations is a standard practice in the biotech sector, especially for companies without approved products.

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• The company's continued losses and need for future financing could impact investor confidence and stock price.
• Employees may face uncertainty due to the company's ongoing financial performance and the need for continued R&D investment.
• Partners and vendors may be impacted by the company's cash burn rate and the need for future capital raises.

Next Steps

• Submit a marketing authorization application (MAA) with the European Medicines Agency (EMA) for varegacestat by the end of 2026.
• Present initial lymphoma data for IM-1021 in 2026.
• Continue Phase 1 trials for IM-1021, IM-1617, and IM-3050.
• Submit IND for IM-1340 in mid-2026.
• Submit IND for IM-1335 in late 2026.
• Continue investing in discovery efforts to expand the pipeline.

Key Dates

Recommendation

While Immunome shows promising clinical development progress, particularly with varegacestat's NDA acceptance, the significant increase in operating expenses and widening net losses, coupled with a substantial decrease in cash reserves, present considerable financial risk. The company's reliance on future capital raises and the long road to potential commercialization warrant a cautious 'hold' stance until profitability and cash flow improve or further de-risking of the pipeline occurs.

Keywords

oncology therapies, antibody-drug conjugates, clinical trials, varegacestat, desmoid tumors, biotechnology, drug development, FDA approval